Breakthrough in “Monkey Fever” Battle: ICMR Launches Human Trials for Indigenous KFD Vaccine

NEW DELHI — In a major step toward securing the health of forest-dwelling communities in South India, the Indian Council of Medical Research (ICMR) has initiated Phase I human clinical trials for a new, improved vaccine against Kyasanur Forest Disease (KFD).

The announcement, made on February 7, 2026, marks a pivotal moment in the fight against “monkey fever,” a tick-borne viral illness that has plagued the Western Ghats for nearly seven decades. The development comes as a collaborative effort between the ICMR–National Institute of Virology (NIV) and Indian Immunologicals Limited (IIL), following an urgent request from the Karnataka state government to address the growing vulnerability of local populations.

A Modern Shield Against an Old Threat

Kyasanur Forest Disease is a viral hemorrhagic fever transmitted to humans through the bite of infected Haemaphysalis spinigera ticks. First identified in 1957 in the Kyasanur Forest of Karnataka, the disease has since expanded its footprint, with cases now regularly reported across Kerala, Tamil Nadu, Goa, and Maharashtra.

The new vaccine candidate is a fully indigenous, two-dose adjuvanted inactivated vaccine. Unlike previous versions, this formulation is designed to provide more robust and long-lasting immunity.

“The initiation of Phase I trials is the culmination of rigorous preclinical work,” the Ministry of Health and Family Welfare stated. “Animal challenge and toxicity studies have already been successfully completed, and GLP-grade (Good Laboratory Practice) vaccine material has been manufactured to ensure the highest safety standards for human participants.”

Why a New Vaccine is Necessary

The drive for a next-generation vaccine stems from the limitations of the earlier formalin-inactivated vaccine, which was discontinued in October 2022. While that vaccine offered some protection, it faced several critical hurdles:

• Waning Immunity: Effectiveness was estimated at 62.4% after two doses but dropped significantly over time, requiring annual boosters for up to five years.

• Production Bottlenecks: The old vaccine was mouse brain-derived, making it difficult to scale up during outbreaks.

• Strain Mismatch: Research suggested that the circulating virus had evolved, making the older vaccine less effective against modern variants.

The new ICMR-IIL vaccine aims to overcome these issues. By using a modern cell-culture platform and an adjuvant—a substance that enhances the body’s immune response—researchers hope to achieve higher efficacy with a simpler dosing schedule: two shots administered 28 days apart.

Understanding the Disease

KFD typically begins abruptly with high fever, frontal headaches, and severe muscle pain. In approximately 10% to 20% of cases, the illness is “biphasic,” meaning patients appear to recover before suffering a second wave of symptoms, including neurological issues like mental confusion and tremors.

The disease primarily affects those whose livelihoods depend on the forest, such as cashew and areca nut farmers, as well as forest department workers. “This is a disease of the marginalized,” says Dr. Ramesh Rao, an infectious disease specialist not involved in the study. “The absence of a vaccine for the last three years has left a significant immunity gap in the Western Ghats. This new candidate isn’t just a scientific milestone; it’s a public health necessity.”

The Road Ahead: Safety First

The current Phase I trial, approved by the Central Drugs Standard Control Organization (CDSCO), will focus primarily on the safety and tolerability of the vaccine in a small group of healthy volunteers.

If Phase I proves the vaccine is safe, the ICMR plans to move quickly into Phase II and III trials to evaluate immunogenicity (the vaccine’s ability to trigger an immune response) and efficacy (how well it prevents the disease in real-world conditions).

Public Health Implications

While the vaccine undergoes testing, health authorities continue to urge residents in endemic areas to take preventive measures:

1. Protective Clothing: Wear long sleeves and tuck trousers into socks when entering forested areas.

2. Repellents: Use tick-repellent oils (like DEPA) on exposed skin.

3. Self-Examination: Check for and remove ticks immediately after returning from the forest.

The Government of India has reaffirmed its commitment to supporting state governments in tackling regional health challenges. If the trials succeed, this vaccine could become the cornerstone of a “One Health” strategy, integrating human vaccination with environmental and animal surveillance to finally bring “monkey fever” under control.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

Study & Regulatory Citations:

• Press Information Bureau (PIB). (2026, Feb 7). ICMR Advances Development of Improved Kyasanur Forest Disease Vaccine. Ministry of Health and Family Welfare. [Release ID: 2224977]